# REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

> **NCT07410117** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 860 (estimated)

## Conditions studied

- Cancer-Associated Thrombosis (CAT)

## Interventions

- **DRUG:** REGN7508
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07410117
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2030-01-23
- **Final completion:** 2030-05-06
- **Target enrollment:** 860 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07410117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07410117, "REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07410117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*